Cargando…
Vidarabin-monophosphate, BCNU, VM26--an in vitro comparative study of active agents in the treatment of malignant human brain tumours.
BCNU (carmustine), VM26 (teniposide) and ARA-A5'P (vidarabin-monophosphate) were compared in their activity against 30 cell lines of primary (N = 21) and metastatic (N = 9) human brain tumours, which were characterized in tissue culture by cytochemical, immunological and cytogenetic criteria. I...
Autores principales: | Bogdahn, U., Zapf, J., Weber, H., Dünisch, G., Löbering, H. G., Martin, R., Mertens, H. G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1987
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002094/ https://www.ncbi.nlm.nih.gov/pubmed/2434122 |
Ejemplares similares
-
An Enzymatic Flow-Based Preparative Route to Vidarabine
por: Tamborini, Lucia, et al.
Publicado: (2020) -
Structural Basis for Inhibition of Human Primase by
Arabinofuranosyl Nucleoside Analogues Fludarabine and Vidarabine
por: Holzer, Sandro, et al.
Publicado: (2019) -
Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo.
por: Jones, A. L., et al.
Publicado: (1990) -
Interstitial chemotherapy with biodegradable BCNU (Gliadel(®)) wafers in the treatment of malignant gliomas
por: Bota, Daniela A, et al.
Publicado: (2007) -
Symptomatic Remote Cyst after BCNU Wafer Implantation for Malignant Glioma
por: MATSUMURA, Hideaki, et al.
Publicado: (2018)